Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 4/2017

01-04-2017 | Original Article

Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters

A single-center analysis

Authors: Müjdat Yildirim, MD, Jens Müller von der Grün, Ria Winkelmann, MD, Emmanouil Fokas, MD, PhD, Franz Rödel, PhD, Hanns Ackermann, PhD, Claus Rödel, MD, Panagiotis Balermpas, MD

Published in: Strahlentherapie und Onkologie | Issue 4/2017

Login to get access

Abstract

Background and purpose

Cervical cancer of unknown primary (CUP) represents an uncommon and heterogeneous subentity of head and neck cancer. However, both optimal diagnostics and therapy remain unclear. An improved understanding of the underlying pathology is essential to enable future tailored therapies and optimized outcomes.

Materials and methods

We retrospectively analyzed 53 patients with head and neck CUP and 48 available cervical lymph node specimens. All patients have received radiotherapy between 2007 and 2015. Preradiotherapy involved lymph node specimens were analyzed for p16 and p53 immunoreactivity. The prognostic relevance of the combined p16 and p53 status and other clinical parameters were examined by univariate and multivariate analyses.

Results

Median patient age was 61.5 years and median irradiation dose to the involved nodal levels was 66 Gy. Of the 48 evaluated specimens, 13 (27%) were p16-positive and 31 (64.6%) p53-positive. After a median follow up of 32.9 months, patients with p16-negative and simultaneously p53-positive tumors showed a significantly inferior tumor-specific survival (TSS) compared to those with either p16+/p53−, p16+/p53+, or p16−/p53− (univariate: p = 0.055, multivariate: p = 0.038). Other factors with an adverse impact on TSS in the univariate analysis were smoking history (p = 0.032) and nodal stage (p = 0.038).

Conclusions

The combined p16- and p53-expression status in cervical metastases of CUP may represent a simple method for risk stratification. Further validation of these biomarkers in large prospective trials is essential to design rational trials for CUP treatment optimization.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917CrossRefPubMed
2.
Zhu L, Wang N (2013) 18F-fluorodeoxyglucose positron emission tomography-computed tomography as a diagnostic tool in patients with cervical nodal metastases of unknown primary site: A meta-analysis. Surg Oncol 22:190–194CrossRefPubMed
3.
Grau C, Johansen LV, Jacobsen J et al (2000) Cervical lymph node metastases from unknown primary tumours: Results from a national survey by the Danish Society for Head and Neck Oncology. Radiother Oncol 55:121–129CrossRefPubMed
4.
Pavlidis N, Briasoulis E, Hainsworth J et al (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39:1990–2005CrossRefPubMed
5.
Pfeiffer J, Kayser L, Ridder GJ (2009) Minimal-invasive core needle biopsy of head and neck malignancies: Clinical evaluation for radiation oncology. Radiother Oncol 90:202–207CrossRefPubMed
6.
Issing WJ, Taleban B, Tauber S (2003) Diagnosis and management of carcinoma of unknown primary in the head and neck. Eur Arch Otorhinolaryngol 260:436–443CrossRefPubMed
7.
Strojan P, Ferlito A, Medina JE (2013) Contemporary management of lymph node metastases from an unknown primary to the neck: I. A review of diagnostic approaches. Head Neck 35:123–132CrossRefPubMed
8.
Chaturvedi AK, Anderson WF, Lortet-Tieulent J et al (2013) Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 31:4550–4559CrossRefPubMedPubMedCentral
9.
Chaturvedi AK, Engels EA, Pfeiffer RM et al (2011) Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29:4294–4301CrossRefPubMedPubMedCentral
10.
Boscolo-Rizzo P, Schroeder L, Romeo S et al (2015) The prevalence of human papillomavirus in squamous cell carcinoma of unknown primary site metastatic to neck lymph nodes: A systematic review. Clin Exp Metastasis 32:835–845CrossRefPubMed
11.
Tribius S, Hoffmann AS, Bastrop S et al (2012) HPV status in patients with head and neck of carcinoma of unknown primary site: HPV, tobacco smoking, and outcome. Oral Oncol 48:1178–1184CrossRefPubMed
12.
Jensen DH, Hedback N, Specht L et al (2014) Human papillomavirus in head and neck squamous cell carcinoma of unknown primary is a common event and a strong predictor of survival. PLOS ONE 4(9):e110456CrossRef
13.
14.
Heiduschka G, Grah A, Oberndorfer F et al (2015) Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy. Strahlenther Onkol 191:209–216CrossRefPubMed
15.
Duffy MJ, Synnott NC, McGowan PM et al (2014) p53 as a target for the treatment of cancer. Cancer Treat Rev 40:1153–1160CrossRefPubMed
16.
Poeta ML, Manola J, Goldwasser MA et al (2007) TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 357:2552–2561CrossRefPubMedPubMedCentral
17.
Agrawal N, Frederick MJ, Pickering CR et al (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333(6046):1154–1157CrossRefPubMedPubMedCentral
18.
Lohaus F, Linge A, Tinhofer I et al (2014) HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiother Oncol 113:317–323CrossRefPubMed
19.
Maestro R, Dolcetti R, Gasparotto D et al (1992) High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene 7:1159–1166PubMed
20.
Strojan P, Ferlito A, Langendijk JA et al (2013) Contemporary management of lymph node metastases from an unknown primary to the neck: II. a review of therapeutic options. Head Neck 35:286–293CrossRefPubMed
21.
Nieder C, Gregoire V, Ang KK et al (2001) Cervical lymph node metastases from occult squamous cell carcinoma: Cut down a tree to get an apple? Int J Radiat Oncol Biol Phys 50:727–733CrossRefPubMed
22.
Park GC, Lee M, Roh JL et al (2012) Human papillomavirus and p16 detection in cervical lymph node metastases from an unknown primary tumor. Oral Oncol 48:1250–1256CrossRefPubMed
23.
Sivars L, Näsman A, Tertipis N et al (2014) Human papillomavirus and p53 expression in cancer of unknown primary in the head and neck region in relation to clinical outcome. Cancer Med 3:376–384CrossRefPubMedPubMedCentral
24.
Keller LM, Galloway TJ, Holdbrook T et al (2014) p16 status, pathologic and clinical characteristics, biomolecular signature, and long-term outcomes in head and neck squamous cell carcinomas of unknown primary. Head Neck 36:1677–1684CrossRefPubMedPubMedCentral
25.
Heiduschka G, Grah A, Oberndorfer F et al (2014) Significance of p16 expression in head and neck cancer patients treated with radiotherapy and cetuximab. Strahlenther Onkol 190:832–838CrossRefPubMed
26.
27.
Wu XC, Zheng YF, Tang M et al (2015) Association between smoking and p53 mutation in Oesophageal squamous cell carcinoma: A Meta-analysis. Clin Oncol (R Coll Radiol) 27:337–344CrossRef
28.
Liu X, Lin XJ, Wang CP et al (2014) Association between smoking and p53 mutation in lung cancer: A meta-analysis. Clin Oncol (R Coll Radiol) 26:18–24CrossRef
29.
30.
Hayes DN, Van Waes C, Seiwert TY (2015) Genetic landscape of human Papillomavirus-associated head and neck cancer and comparison to tobacco-related tumors. J Clin Oncol 33:3227–3234CrossRefPubMedPubMedCentral
31.
Masterson L, Moualed D, Liu ZW et al (2014) De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials. Eur J Cancer 50:2636–2648CrossRefPubMed
32.
Wallace A, Richards GM, Harari PM (2011) Head and neck squamous cell carcinoma from an unknown primary site. Am J Otolaryngol 32:286–290CrossRefPubMed
33.
34.
Hühns M, Simm G, Erbersdobler A et al (2015) HPV infection, but not EBV or HHV-8 infection, is associated with salivary gland tumours. Biomed Res Int 2015:829349CrossRefPubMedPubMedCentral
35.
36.
Remo A, Pancione M, Zanella C et al (2016) p16 expression in prostate cancer and nonmalignant lesions: Novel findings and review of the literature. Appl Immunohistochem Mol Morphol 24:201–206CrossRefPubMed
37.
Qian X, Kaufmann AM, Chen C et al (2016) Prevalence and associated survival of high-risk HPV-related adenoid cystic carcinoma of the salivary glands. Int J Oncol 49:803–811PubMed
38.
Fizazi K, Greco FA, Pavlidis N (2015) Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v133–v138CrossRefPubMed
Metadata
Title
Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters
A single-center analysis
Authors
Müjdat Yildirim, MD
Jens Müller von der Grün
Ria Winkelmann, MD
Emmanouil Fokas, MD, PhD
Franz Rödel, PhD
Hanns Ackermann, PhD
Claus Rödel, MD
Panagiotis Balermpas, MD
Publication date
01-04-2017
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 4/2017
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-017-1102-4

Other articles of this Issue 4/2017

Strahlentherapie und Onkologie 4/2017 Go to the issue

Original Article

Role of postoperative radiotherapy in the management of malignant pleural mesothelioma

Original Article

Neoadjuvant radiotherapy followed by mastectomy and immediate breast reconstruction

Original Article

Radiotherapy for aneurysmal bone cysts

Literatur kommentiert

Stereotaktische Radiochirurgie bei Metastasen im Hirnstamm

Review Article

Monte Carlo systems used for treatment planning and dose verification

Original Article

DART-bid for loco-regionally advanced NSCLC